Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Global Pharmaceutical Companies Turn to Wolters Kluwer to Boost Research Automation & Efficiency

Custom-built, medical research workflows advance pharma discovery

In the highly regulated pharmaceutical industry, implementing the latest technologies to help bring medical breakthroughs to market is of critical importance. That is why Wolters Kluwer Health has collaborated with some of the leading pharmaceutical companies to bring intuitive and easy-to-use workflows to the Ovid® research platform.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240509872202/en/

Wolters Kluwer Health has collaborated with some of the leading pharmaceutical companies to bring intuitive and easy-to-use workflows to the Ovid® research platform (Photo: Business Wire)

Wolters Kluwer Health has collaborated with some of the leading pharmaceutical companies to bring intuitive and easy-to-use workflows to the Ovid® research platform (Photo: Business Wire)

Scaling up customizable solutions

The pharma and biotech industries rely on obtaining the latest, most comprehensive clinical information to effectively do their jobs. Automation and efficiency are imperative to manage the massive volumes of information within regulatory, clinical writing, medical affairs, pharmacovigilance, health economics and outcomes research, or publications groups. This allows different organizational functions to complete key tasks with speed and accuracy, such as leveraging hard-to-find data to generate study designs, substantiating findings for regulatory agencies, and gathering the latest information regarding disease management.

“Each pharmaceutical, life sciences and biomedical organization must adhere to strict regulatory guidelines, while also having unique needs for their specific business focus. Providing those institutions with an expert solution that is flexible, while continuously supplying authoritative information in a timely and digestible manner, is crucial,” said Rafael Sidi, Senior Vice President & General Manager of Health Research, Wolters Kluwer Health. “The Ovid research platform is uniquely positioned to support this industry, empowering researchers by putting essential information from a vast array of trusted resources at their fingertips.”

Improving workflow and productivity through understanding researchers’ tasks

Ovid medical research solutions enhance search precision and workflow speed to maximize research productivity. Teams improve their efficiency with more focused results, drug-specific keywording, and a clear path to the full text of relevant research. Additionally, the platform helps reduce administrative overhead, by freeing team members to spend more time on stakeholder engagement and regulatory requirements.

Wolters Kluwer worked with the world’s top pharmaceutical company to develop new enhancements in the Ovid research platform that will improve research automation and efficiency across the industry. New research tool updates include:

  • Rapid “find and replace” search updating: Manual updates of proprietary searches when a field changes in a database reload or a drug rename, are now a thing of the past. Users can search for a string within Saved Searches and AutoAlerts and replace all instances at once.
  • AutoAlert bulk editing: To help with administrative tasks when there is a new stakeholder or staff turnover, multiple edits to AutoAlerts can be made at one time, ensuring the right people, receive the right information, at the right time.
  • Change Audit History: Every AutoAlert change is logged, recording when it was run, edited, or suspended and the user making the change. This is extremely important to help with regulation tracking and compliance.

Learn more about the vital role that the Ovid research platform can play for pharma organizations and review this case study on how an international, rare drug manufacturer is currently leveraging the platform’s tools to accelerate their research.

For more information about Wolters Kluwer, please visit: www.wolterskluwer.com

About Wolters Kluwer

Wolters Kluwer (EURONEXT: WKL) is a global leader in information, software solutions and services for professionals in healthcare; tax and accounting; financial and corporate compliance; legal and regulatory; corporate performance and ESG. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with technology and services.

Wolters Kluwer reported 2023 annual revenues of €5.6 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 21,400 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.

For more information, visit www.wolterskluwer.com, follow us on LinkedIn, Facebook, YouTube and Instagram.

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.